Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.

Abstract

A multicentre, double-blind, randomised trial was conducted to compare the efficacy of a low-molecular-weight (LMW) heparin, Logiparin, with that of an unfractionated (UF) heparin in the prophylactic treatment of thrombosis in patients undergoing general surgery. A total of 1,290 patients were randomised to receive a single daily dose of Logiparin (2,500 IU: 431 patients; 3,500 IU: 430 patients) or UF heparin (2 x 5,000 IU: 429 patients). The incidence of the main end point, deep venous thrombosis, was found to be significantly different between the groups (p = 0.03), whereas the incidence of severe haemorrhage was not (p = 0.05). The plasma anti-Xa activity was found to be correlated with body weight, but correlated only very weakly with antithrombotic activity (p = 0.045) after adjustment in a stepwise multivariate analysis, and did not significantly correlate with the incidence of haemorrhage. Logiparin at 3,500 IU and UF heparin showed similar efficacy. Although a correlation between plasma anti-Xa activity and body weight was observed, there is not sufficient evidence to recommend the adjustment of the Logiparin dose on patient's weight for prophylaxis in general surgery patients.

• Authors: A Leizorovicz, L Bara, M M Samama, M C Haugh
• Journal: Haemostasis (Haemostasis) Vol. 23 Suppl 1 Pg. 89-98 (Mar 1993) ISSN: 0301-0147 [Print] Switzerland
• PMID: 8388357 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Factor Xa Inhibitors
• Heparin, Low-Molecular-Weight
• Heparin

Topics

• Body Weight
• Double-Blind Method
• Factor Xa Inhibitors
• Female
• Hemorrhage (chemically induced, epidemiology)
• Heparin (adverse effects, therapeutic use)
• Heparin, Low-Molecular-Weight (adverse effects, blood, pharmacology, therapeutic use)
• Humans
• Incidence
• Male
• Middle Aged
• Postoperative Care
• Postoperative Complications (epidemiology, prevention & control)
• Pulmonary Embolism (epidemiology, prevention & control)
• Thrombophlebitis (epidemiology, prevention & control)